You are here


Biolidics issues letter of demand to biochip partner Sysmex over IP matters


A CATALIST-LISTED medtech firm that made strong gains this year as investors hunted for exposure to tech plays and Covid-19 test makers, has now claimed that a Japanese group breached intellectual property-related (IP) agreements.

Biolidics has issued a letter of demand...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to